Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

OcuMension Buys Dry Eye Treatments from Alcon for $110 Million of Shares

publication date: Aug 13, 2024

Shanghai OcuMension acquired Chinese rights to a portfolio of dry eye treatments from Alcon in exchange for a 16.7% stake in OcuMension’s shares. The shares, which are worth about US$110 million, will make Alcon one of OcuMension’s largest shareholders. Each company will also grant the other company a right of first negotiation over future products. OcuMension is an ophthalmic pharmaceutical company with a portfolio of 25 pharmaceutical assets. Alcon is a global company focused on offering eye care products. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here